Ratings HCA Healthcare, Inc.

Equities

HCA

US40412C1018

Real-time Estimate Cboe BZX 03:15:44 2024-03-28 pm EDT 5-day change 1st Jan Change
333.7 USD +0.61% Intraday chart for HCA Healthcare, Inc. +1.60% +23.43%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company is in debt and has limited leeway for investment
  • The company is not the most generous with respect to shareholders' compensation.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
+23.43% 87.73B
C+
+1.17% 99.96B
B-
+10.42% 29.33B
C+
-4.01% 18.21B
B
-3.24% 14.51B
A-
+20.26% 12.22B
B-
+31.62% 12B
B-
+0.17% 11.94B
A-
-13.00% 11.63B
B-
-32.28% 11.56B - -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes